Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | RXRA | P19793 | 1/20 | 0.61 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.61 |
| ▸ | TOP1 | P11387 | 3/20 | 0.57 |
| ▸ | PPARD | Q03181 | 5/20 | 0.54 |
| ▸ | PPARA | Q07869 | 5/20 | 0.54 |
| ▸ | TERT | O14746 | 3/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | BLM | P54132 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | FABP4 | P15090 | 3/20 | 0.54 |
| ▸ | F7 | P08709 | 3/20 | 0.54 |
| ▸ | F3 | P13726 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17473895 | 1.00 | PPARG (0.61) | PPARGMAPTCYP19A1FFAR1ALDH1A1 | |
| SCHEMBL466117 | 1.00 | PPARG (0.61) | PPARGMAPTCYP19A1FFAR1ALDH1A1 | |
| SCHEMBL2441819 | 0.97 | PPARG (0.64) | PPARGMAPTCYP19A1FFAR1ALDH1A1 | |
| SCHEMBL586010 | 0.97 | PPARG (0.64) | PPARGMAPTCYP19A1FFAR1ALDH1A1 | |
| SCHEMBL1664949 | 0.97 | PPARG (0.64) | PPARGMAPTCYP19A1FFAR1ALDH1A1 | |
| Formaldehyde SCHEMBL18443348 | 0.93 | PPARG (0.59) | PPARGMAPTCYP19A1FFAR1ALDH1A1 | |
| Formaldehyde SCHEMBL18443347 | 0.93 | PPARG (0.59) | PPARGMAPTCYP19A1FFAR1ALDH1A1 | |
| SCHEMBL19193490 | 0.91 | ALDH1A1 (0.76) | PPARGMAPTCYP19A1FFAR1ALDH1A1 | |
| SCHEMBL20397376 | 0.91 | ALDH1A1 (0.76) | PPARGMAPTCYP19A1FFAR1ALDH1A1 | |
| SCHEMBL31461009 | 0.91 | ALDH1A1 (0.76) | PPARGMAPTCYP19A1FFAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120053661-A | Hydrophilic fatty acid complex for preventing, preventing or treating microbial infection, preparation and application thereof | 太阳雨林(北京)生物医药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120053660-A | Hydrophilic complex for preventing, preventing or treating microbial infection, preparation and application thereof | 太阳雨林(北京)生物医药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119855607-A | Carbon chain substance for regulating transmembrane transport and fluidity of cell membrane, preparation and application | 太阳雨林(北京)生物医药有限公司 | 2025-04-18 | — | — | CN | disclosed |
| WO-2023213310-A9 | CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF | 太阳雨林(北京)生物医药有限公司 | 2025-02-20 | — | — | WO | disclosed |
| WO-2023213310-A1 | CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF | 太阳雨林(北京)生物医药有限公司 | 2023-11-09 | — | — | WO | disclosed |
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | JINA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| CN-115607677-A | Compound for preventing, preventing or treating microbial infection and preparation and application thereof | 太阳雨林(北京)生物医药有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-114788872-A | Compound for preventing, preventing or treating microbial infection and preparation and application thereof | 太阳雨林(北京)生物医药有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114569726-A | Compound for preventing, preventing or treating microbial infection and preparation method and application thereof | 太阳雨林(北京)生物医药有限公司 | 2022-06-03 | — | — | CN | disclosed |
| US-20210177752-A1 | ENDOXIFEN METHODS AND COMPOSITIONS FOR INHIBITION OF PROTEIN KINASE C | JINA PHARMACEUTICALS, INC. | 2021-06-17 | — | — | US | disclosed |
| US-20050266068-A1 | Cardiolipin molecules and methods of synthesis | NEOPHARM, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| US-20050181037-A1 | Cardiolipin compositions their methods of preparation and use | NEOPHARM, INC. (US) | 2005-08-18 | — | — | US | disclosed |
| EP-1556392-A1 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | Neopharm, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1513853-A2 | CARDIOLIPIN COMPOSITIONS, METHODS OF PREPARATION AND USE | Neopharm, Inc. (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004039817-A9 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | NEOPHARM INC (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004039817-A1 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | NEOPHARM, INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-2003099830-A2 | CARDIOLIPIN COMPOSITIONS, METHODS OF PREPARATION AND USE | NEOPHARM, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003027379-A1 | WOOL LUBRICANT | HUNTSMAN CORPORATION AUSTRALIA PTY LTD (AU) | 2003-04-03 | — | — | WO | disclosed |
| EP-0345082-A2 | Enzyme formation suppressing agent | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 1989-12-06 | — | — | EP | disclosed |
| EP-0345081-A2 | Enzyme formation suppressing agent | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177752-A1 | ENDOXIFEN METHODS AND COMPOSITIONS FOR INHIBITION OF PROTEIN KINASE C | EEF2K, LITAF, RAPGEF3 | PPARG 846/4885MAPT 268/4885CYP19A1 2136/4885 |
| US-20050266068-A1 | Cardiolipin molecules and methods of synthesis | PHOSPHO1, MGLL, LIPA | PPARG 453/4885MAPT 4872/4885CYP19A1 3639/4885 |
| US-20050181037-A1 | Cardiolipin compositions their methods of preparation and use | LIPA, LCLAT1, PHOSPHO1 | PPARG 386/4885MAPT 4815/4885CYP19A1 1481/4885 |
| US-11672758-B2 | Endoxifen methods and compositions for inhibition of protein kinase C | EEF2K, LITAF, RAPGEF3 | PPARG 846/4885MAPT 268/4885CYP19A1 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.